Literature DB >> 34196118

Triazolyl-Functionalized N-Heterocyclic Carbene Half-Sandwich Compounds: Coordination Mode, Reactivity and in vitro Anticancer Activity.

Kelvin K H Tong1,2, Muhammad Hanif1,2, Sanam Movassaghi1, Matthew P Sullivan1,2,3, James H Lovett4, Katja Hummitzsch5, Tilo Söhnel1, Stephen M F Jamieson2,6, Suresh K Bhargava7, Hugh H Harris4, Christian G Hartinger1,2.   

Abstract

We report investigations on the anticancer activity of organometallic [MII/III (η6 -p-cymene/η5 -pentamethylcyclopentadienyl)] (M=Ru, Os, Rh, and Ir) complexes of N-heterocyclic carbenes (NHCs) substituted with a triazolyl moiety. Depending on the precursors, the NHC ligands displayed either mono- or bidentate coordination via the NHC carbon atom or as N,C-donors. The metal complexes were investigated for their stability in aqueous solution, with the interpretation supported by density functional theory calculations, and reactivity to biomolecules. In vitro cytotoxicity studies suggested that the nature of both the metal center and the lipophilicity of the ligand determine the biological properties of this class of compounds. The IrIII complex 5 d bearing a benzimidazole-derived ligand was the most cytotoxic with an IC50 value of 10 μM against NCI-H460 non-small cell lung carcinoma cells. Cell uptake and distribution studies using X-ray fluorescence microscopy revealed localization of 5 d in the cytoplasm of cancer cells.
© 2021 Wiley-VCH GmbH.

Entities:  

Keywords:  anticancer activity; biomolecule reactions; bioorganometallics; coordination mode; intracellular distribution

Mesh:

Substances:

Year:  2021        PMID: 34196118     DOI: 10.1002/cmdc.202100311

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  1 in total

Review 1.  Current status of iridium-based complexes against lung cancer.

Authors:  Tongfu Yang; Minghui Zhu; Ming Jiang; Feng Yang; Zhenlei Zhang
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.